Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 8:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hypothalamic-pituitary Disorders Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Glucagon Stimulation Test for Evaluation of Adult Growth Hormone Deficiency and Adrenocorticotropic Axis

NCT01282164
View directory record Official record
Conditions
Adult Growth Hormone Deficiency, Hypothalamic-pituitary Disorders
Interventions
glucagon stimulation test and insulin tolerance test
Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
4
States / cities
Boston, Massachusetts • Cleveland, Ohio • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated May 16, 2017 · Synced Jul 23, 2026, 8:51 AM EDT
Not listed No phase listed Observational

Prevalence of Pituitary Incidentaloma in Relatives of Patients With Pituitary Adenoma

NCT00598949
View directory record Official record
Conditions
Pituitary Tumor
Interventions
Not listed
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 14, 2010 · Synced Jul 23, 2026, 8:51 AM EDT
Completed Phase 3 Interventional Results available

Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Adult and Adolescent Subjects With Perennial Allergic Rhinitis (PAR)

NCT01133626
View directory record Official record
Conditions
Perennial Allergic Rhinitis
Interventions
Placebo Nasal Aerosol, Prednisone capsules, Placebo Prednisone Capsules, Beclomethasone dipropionate
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years to 45 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
3
States / cities
North Dartmouth, Massachusetts • New Braunfels, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 3, 2012 · Synced Jul 23, 2026, 8:51 AM EDT
Recruiting No phase listed Observational

Collecting Information About Treatment Results for Patients With Cushing's Syndrome

NCT03364803
View directory record Official record
Conditions
Cushing's Disease, Cushing Syndrome, Cushing Disease
Interventions
Cushing's QoL (Quality of Life Questionnaire), Nottingham Health Profile (NHP), Hospital Anxiety and Depression Scale (HADS), Perceived Stress Scale (PSS), Barratt's Impulsivity Scale (BIS), Beck Depression Inventory (BDI), State-Trait Anxiety Inventory (STAI), State Food Craving Questionnaire-State (FCQ-S), Trait Food Craving Questionnaire-Trait (FCQ-T), Visual Analogue Scale (VAS), Sensitivity to Reinforcement of Addictive and other Primary Rewards (STRAP-R) food variant
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
14 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Jul 23, 2026, 8:51 AM EDT
Not listed Phase 3 Interventional Results available

Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly

NCT03252353
View directory record Official record
Conditions
Acromegaly
Interventions
octreotide capsules, Matching placebo
Drug
Lead sponsor
Chiasma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
19
States / cities
Los Angeles, California • Palo Alto, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2020 · Synced Jul 23, 2026, 8:51 AM EDT
Recruiting Phase 2 Interventional

Growth Hormone Replacement Therapy for Retried Professional Football Players

NCT04121780
View directory record Official record
Conditions
TBI (Traumatic Brain Injury), Concussion, Brain, Sport Injury, Anterior Pituitary Hyposecretion Syndrome, Hypopituitarism, Growth Hormone Deficiency
Interventions
Growth Hormone, Placebo
Biological · Other
Lead sponsor
Center for Neurological Studies
Other
Eligibility
18 Years to 76 Years · Male only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Dearborn, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 7, 2023 · Synced Jul 23, 2026, 8:51 AM EDT
Terminated No phase listed Observational

Tegaderm and Visual Evoked Potentials

NCT02105337
View directory record Official record
Conditions
Tumor of Pituitary and Suprasellar Region
Interventions
Not listed
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 10, 2015 · Synced Jul 23, 2026, 8:51 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate the Long-Term Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Advance)

NCT04261712
View directory record Official record
Conditions
Acromegaly
Interventions
Paltusotine
Drug
Lead sponsor
Crinetics Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
7
States / cities
Los Angeles, California • Chicago, Illinois • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 23, 2026, 8:51 AM EDT
Recruiting Phase 3 Interventional

Growth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficiency (AGHD)

NCT04867317
View directory record Official record
Conditions
Adult Growth Hormone Deficiency, Mild Traumatic Brain Injury
Interventions
Somatropin, Placebo
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years to 55 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
16
States / cities
Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Jul 23, 2026, 8:51 AM EDT
Completed No phase listed Observational

rhGH Therapy on Hepatic Drug Metabolism

NCT00458991
View directory record Official record
Conditions
Growth Hormone Deficiency, Dwarfism
Interventions
Dextromethorphan and Caffeine
Drug
Lead sponsor
University of Louisville
Other
Eligibility
4 Years to 14 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
4
States / cities
San Diego, California • Louisville, Kentucky • Kansas City, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Jul 23, 2026, 8:51 AM EDT
Completed No phase listed Observational

International, Multicenter Study of a Twenty-eight Week, Open-label, Titrated Oral Lixivaptan Administration in Patients With Chronic Hyponatremia: Extension to Studies CK-LX3401, 3405, and 3430

NCT01056848
View directory record Official record
Conditions
Hyponatremia With Normal Extracellular Fluid Volume, Hyponatremia With Excess Extracellular Fluid Volume
Interventions
Not listed
Lead sponsor
CardioKine Inc.
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
6
States / cities
Lomita, California • Clearewater, Florida • Fleming Island, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2011 · Synced Jul 23, 2026, 8:51 AM EDT
Completed No phase listed Observational

Acute Side Effects in Patients Who Are Undergoing Stereotactic Radiosurgery for Brain Tumors or Other Brain Disorders

NCT00255671
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Metastatic Cancer, Radiation Toxicity
Interventions
Questionnaire
Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 26, 2020 · Synced Jul 23, 2026, 8:51 AM EDT
Terminated Phase 4 Interventional Results available

Study of Amantadine for Risperidone Consta or Paliperidone Treated Patients to Decrease Prolactin Elevation

NCT00975611
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Amantadine Hydrochloride, USP, Placebo
Drug
Lead sponsor
David C. Henderson, MD
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 9, 2013 · Synced Jul 23, 2026, 8:51 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

304-C03/L3301n: Effects of Growth Hormone on Glucose and Protein Metabolism in Children With Growth Hormone Deficiency

NCT00362063
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
growth hormone (Nutropin)
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Month to 17 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Jul 23, 2026, 8:51 AM EDT
Completed No phase listed Observational

The Treatment and Natural History of Acromegaly

NCT00001981
View directory record Official record
Conditions
Acromegaly, Pituitary Neoplasm
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 26, 2020 · Synced Jul 23, 2026, 8:51 AM EDT
Completed No phase listed Observational

Peri-operative Dynamics of the Growth Hormone Axis in Subjects With Acromegaly

NCT00921609
View directory record Official record
Conditions
Acromegaly
Interventions
Oral glucose tolerance test
Diagnostic Test
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Jul 23, 2026, 8:51 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The IGFBP-3 Stimulation Test: A New Tool for the Diagnosis of Growth Hormone Deficiency in Children.

NCT00235599
View directory record Official record
Conditions
Short Stature, Growth Hormone Deficiency
Interventions
IGFBP-3 Stimulation Test
Procedure
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
4 Years to 12 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 16, 2007 · Synced Jul 23, 2026, 8:51 AM EDT
Completed Not applicable Interventional Results available

Peri-Operative Steroid Management in Patients

NCT02084134
View directory record Official record
Conditions
Pituitary Adenoma, Pituitary Diseases
Interventions
hydrocortisone, dexamethasone
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 10, 2018 · Synced Jul 23, 2026, 8:51 AM EDT
Terminated No phase listed Observational

Validation of a Quality of Life Metric "Prolac-10"

NCT04106531
View directory record Official record
Conditions
Prolactinoma, Prolactin-Producing Pituitary Tumor, Pituitary Tumor, Prolactinoma Macroadenoma, Prolactinoma Microadenoma
Interventions
Not listed
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Jul 23, 2026, 8:51 AM EDT
Recruiting Phase 4 Interventional

68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.

NCT04081701
View directory record Official record
Conditions
CNS Tumors, Meningioma, Esthesioneuroblastoma, Hemangioblastoma, Medulloblastoma, Paraganglioma, Pituitary Adenoma
Interventions
Ga68-DOTATATE-PET/MRI
Diagnostic Test
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 100 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2038
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Jul 23, 2026, 8:51 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Study of MAR002 in Healthy Men

NCT07195175
View directory record Official record
Conditions
Acromegaly
Interventions
MAR002, Placebo
Drug
Lead sponsor
Marea Therapeutics
Industry
Eligibility
18 Years to 40 Years · Male only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced Jul 23, 2026, 8:51 AM EDT
Terminated Phase 4 Interventional Results available

The Luveris In Vitro Fertilization Trial

NCT00889512
View directory record Official record
Conditions
Infertility, Hypothalamic Amenorrhea, Hyperprolactinemia
Interventions
Luveris fixed dose, Luveris increasing dose
Drug
Lead sponsor
University Reproductive Associates
Other
Eligibility
18 Years to 38 Years · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Hasbrouck Heights, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 6, 2018 · Synced Jul 23, 2026, 8:51 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of LUM-201 in Children With Growth Hormone Deficiency (OraGrowtH210 Trial)

NCT04614337
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
LUM-201, rhGH Norditropin® pen (34 µg/kg)
Drug
Lead sponsor
Lumos Pharma
Industry
Eligibility
3 Years to 12 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
27
States / cities
Sacramento, California • San Diego, California • Greenwood Village, Colorado + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Jul 23, 2026, 8:51 AM EDT
Completed Phase 4 Interventional Results available

Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly

NCT02060383
View directory record Official record
Conditions
Cushing's Disease, Acromegaly
Interventions
Pasireotide s.c., Sitagliptin, Liraglutide, Insulin, Pasireotide LAR, Metformin
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
15
States / cities
Multiple Locations, California • Torrance, California • Ventura, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 28, 2019 · Synced Jul 23, 2026, 8:51 AM EDT